Q & M Dental Group (Singapore) Limited: FY2025 Financial Analysis
Q & M Dental Group (Singapore) Limited, a leading dental services provider with operations in Singapore, Malaysia, and China, released its condensed financial statement for the year ended 31 December 2025. This analysis covers key financial metrics, performance trends, dividends, significant corporate actions, and outlook for investors.
Key Financial Metrics & Comparisons
| Metric |
2H 2025 |
1H 2025 |
2H 2024 |
FY 2025 |
FY 2024 |
YoY Change |
QoQ Change |
| Revenue |
\$108.8m |
\$88.4m |
\$91.5m |
\$197.2m |
\$180.7m |
+9% |
+19% |
| Net Profit |
\$5.9m |
\$4.0m |
\$2.7m |
\$9.9m |
\$12.7m |
-22% |
+123% |
| EPS (cents) |
0.58 |
0.40 |
0.49 |
0.98 |
1.51 |
-35% |
+18% |
| Dividend (per share, cents) |
0.42 (2nd Interim) |
0.40 (1st Interim) |
0.70 (2nd Interim) |
0.82 |
1.10 |
-25% |
-40% |
| Net Assets Value (per share, cents) |
11.1 |
– |
11.1 |
11.1 |
11.1 |
0% |
0% |
Performance Trends & Exceptional Items
- Core Dental Business: Revenue increased strongly (FY25: +12%), mainly due to consolidation of Aoxin Q & M from associate to subsidiary and growth in Singapore clinics.
- Other Businesses: Revenue plunged 68% YoY due to cessation of the Group’s medical laboratory business.
- Profit: Despite higher revenue, net profit and EPS dropped YoY due to higher expenses, impairment charges, and consolidation-related losses.
- Exceptional Items:
- Impairment charges from closure of medical lab (\$6m in FY24).
- Loss on consolidation of associates to subsidiaries (\$4.2m in FY25).
- Legal/professional fees and new MTN issuances increased finance costs.
- Restatements: Prior financials for FY24 were restated due to overclaim issues at Chinese hospitals. Retained earnings and investment in associates were reduced accordingly.
- Cash Flow: Group ended FY25 with \$117.1m in cash, up sharply from \$34.3m, mainly due to MTN issuance and rights issue proceeds.
- Dividends: Total dividend payout for FY25 is lower than FY24 (FY25: \$7.75m vs. FY24: \$10.43m).
Corporate Actions & Events
- Consolidation of Aoxin Q & M and EM2AI: Both were moved from equity-accounted associates to subsidiaries, resulting in significant increases in goodwill and non-current assets.
- Rights Issue: Aoxin Q & M raised \$15.3m; all proceeds remain unutilized as at period end, earmarked for expansion, acquisitions, and working capital.
- Medium Term Note (MTN): \$130m issued in July 2025, boosting cash and increasing finance costs.
- Share Buyback: 6.96m shares bought back, held as treasury shares, reducing shares outstanding.
Dividend Summary
| Dividend |
FY25 |
FY24 |
Change |
| First Interim (cents/share) |
0.40 |
0.40 |
0% |
| Second Interim (cents/share) |
0.42 |
0.70 |
-40% |
| Total Dividend (cents/share) |
0.82 |
1.10 |
-25% |
| Total Dividend (\$m) |
\$7.75 |
\$10.43 |
-25% |
Chairman’s Statement & Outlook
“Barring any unforeseen circumstances, there are no known significant changes in the trends and competitive conditions of the industry in which the Group operates and no other major known factors or events that may adversely affect the Group in the next reporting period and the next 12 months.
As part of its regional expansion strategy, the Group is actively pursuing strategic mergers and acquisitions across Singapore and the Asia Pacific region. The Group intends to adopt a partnership-driven acquisition model, where consideration is structured as a combination of cash and equity… By participating in the broader value creation of the Group, including regional expansion initiatives and operational synergies, partners are incentivised to adopt a collective growth mindset and contribute to sustainable performance across all markets.
In respect of the People’s Republic of China (“PRC”), the Group intends to pursue expansion initiatives through its subsidiary, Aoxin Q & M, leveraging its established operating platform, local regulatory familiarity and network presence. The Group notes the announced expansion plans of Aoxin Q & M to potentially deploy approximately RMB43.7 million (or S\$8.0 million) towards acquisitions of established dental clinic chains outside North-Eastern China, as and when suitable targets are identified. These initiatives are aligned with the Group’s broader regional diversification strategy and disciplined capital allocation framework.”
The statement is positive in tone, emphasizing continued expansion, M&A activity, and disciplined capital allocation. No major risk factors are highlighted.
Significant Events & Corporate Actions
- Restatement of FY24 Results: Triggered by excess claims at Chinese hospitals; led to reduction in prior year earnings and equity.
- Cessation of Medical Laboratory Business: Major drag on “other businesses” segment revenue and profit.
- MTN Issuance: Improved liquidity but increased finance costs.
- Substantial Share Buybacks: Reduced shares outstanding, potentially supporting EPS.
Conclusion & Recommendations
Overall Assessment:
The Group’s financial performance is neutral to slightly positive. Revenue growth is strong in the core dental business, but net profit and EPS declined YoY due to higher expenses, impairment charges, and losses from consolidation of associates. Dividend payout is lower than previous years. Cash position is strong, supported by MTN proceeds and rights issue.
- If you are currently holding the stock:
- Consider holding your position, as the Group’s outlook remains positive and expansion plans are underway. The strong cash position, ongoing M&A, and continued growth in core dental clinics support future performance.
- Monitor for improved profitability and dividend recovery, as current YoY declines are largely due to one-off events and consolidation costs.
- If you are not currently holding the stock:
- Consider initiating a position if you seek exposure to healthcare and dental services with a regional expansion story. However, be mindful of the recent decline in net profit and dividends, and watch for signs of sustainable earnings growth and execution of expansion plans.
Disclaimer:
This analysis is based strictly on the company’s reported financials for FY2025. It does not constitute investment advice. Investors should conduct their own research and consult with professional advisors before making any investment decisions.
View Q&M Dental Historical chart here
